Stock BICX BIOCORRX INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News BioCorRx Inc.

Equities

BICX

US09073C2052

Market Closed - OTC Markets
Other stock markets
 11:39:19 23/05/2024 pm IST 		5-day change 1st Jan Change
0.81 USD +1.25% Intraday chart for BioCorRx Inc. -10.00% +3.85%
03/04 BioCorRx Inc. Announces Board Resignations CI
01/04 BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioCorRx Reports Business Update for the First Quarter of 2024
AQ
BioCorRx Inc. Announces Board Resignations
CI
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
AQ
BioCorRx Reports Business Update for 2023
AQ
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
AQ
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
AQ
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors
CI
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
AQ
BioCorRx Inc. Announces President Changes
CI
BioCorRx : Material Agreement - Form 8-K
PU
BioCorRx Inc. announced that it has received $0.2 million in funding
CI
BioCorRx Reports Business Update for the Third Quarter of 2023
AQ
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
BioCorRx Inc. announced that it has received $0.2 million in funding
CI
Biocorrx Inc. Announces Management Changes
CI
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
AQ
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
CI
BioCorRx Reports Business Update for the Second Quarter of 2023
AQ
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BICX Stock
  4. News BioCorRx Inc.